JP2019519553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519553A5 JP2019519553A5 JP2018566519A JP2018566519A JP2019519553A5 JP 2019519553 A5 JP2019519553 A5 JP 2019519553A5 JP 2018566519 A JP2018566519 A JP 2018566519A JP 2018566519 A JP2018566519 A JP 2018566519A JP 2019519553 A5 JP2019519553 A5 JP 2019519553A5
- Authority
- JP
- Japan
- Prior art keywords
- pinf
- mutant
- variant
- seq
- pig
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282898 Sus scrofa Species 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 208000036142 Viral infection Diseases 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000009385 viral infection Effects 0.000 claims 5
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 241000282887 Suidae Species 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 239000004234 Yellow 2G Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 239000004229 Alkannin Substances 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 208000022555 Genital disease Diseases 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 241000202347 Porcine circovirus Species 0.000 claims 1
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 201000010740 swine influenza Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022098147A JP7441892B2 (ja) | 2016-06-20 | 2022-06-17 | ペグ化ブタインターフェロンおよびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352163P | 2016-06-20 | 2016-06-20 | |
| US62/352,163 | 2016-06-20 | ||
| PCT/US2017/037964 WO2017222940A1 (en) | 2016-06-20 | 2017-06-16 | Pegylated porcine interferon and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022098147A Division JP7441892B2 (ja) | 2016-06-20 | 2022-06-17 | ペグ化ブタインターフェロンおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519553A JP2019519553A (ja) | 2019-07-11 |
| JP2019519553A5 true JP2019519553A5 (enExample) | 2020-01-30 |
| JP7093311B2 JP7093311B2 (ja) | 2022-06-29 |
Family
ID=59258379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566519A Active JP7093311B2 (ja) | 2016-06-20 | 2017-06-16 | ペグ化ブタインターフェロンおよびその使用方法 |
| JP2022098147A Active JP7441892B2 (ja) | 2016-06-20 | 2022-06-17 | ペグ化ブタインターフェロンおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022098147A Active JP7441892B2 (ja) | 2016-06-20 | 2022-06-17 | ペグ化ブタインターフェロンおよびその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10960080B2 (enExample) |
| EP (1) | EP3471755B1 (enExample) |
| JP (2) | JP7093311B2 (enExample) |
| KR (2) | KR102409470B1 (enExample) |
| CN (2) | CN117024562A (enExample) |
| AU (2) | AU2017280958A1 (enExample) |
| BR (1) | BR112018076437A2 (enExample) |
| CA (1) | CA3028683A1 (enExample) |
| CL (1) | CL2018003697A1 (enExample) |
| DK (1) | DK3471755T3 (enExample) |
| EA (1) | EA036509B1 (enExample) |
| ES (1) | ES2793773T3 (enExample) |
| MX (1) | MX391970B (enExample) |
| NZ (1) | NZ749962A (enExample) |
| PL (1) | PL3471755T3 (enExample) |
| PT (1) | PT3471755T (enExample) |
| WO (1) | WO2017222940A1 (enExample) |
| ZA (1) | ZA201808352B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3377488T3 (da) | 2015-11-19 | 2022-10-03 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| MY199705A (en) | 2015-12-22 | 2023-11-20 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| KR102641030B1 (ko) | 2016-12-22 | 2024-02-29 | 인사이트 코포레이션 | Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체 |
| WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| BR112020022936A2 (pt) | 2018-05-11 | 2021-02-02 | Incyte Corporation | derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1 |
| US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
| CN110343164A (zh) * | 2019-08-22 | 2019-10-18 | 安阳工学院 | 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用 |
| MX2022003578A (es) | 2019-09-30 | 2022-05-30 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores. |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| CN113845599B (zh) * | 2021-11-01 | 2023-09-19 | 长春萤火虫生物科技有限公司 | 一种重组猪干扰素融合蛋白及其应用 |
| AR131133A1 (es) | 2023-05-24 | 2025-02-19 | Ambrx Inc | INTERFERÓN l BOVINO PEGILADO Y MÉTODOS DE USO DEL MISMO |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858409B1 (en) * | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| PT730470E (pt) * | 1993-11-10 | 2002-08-30 | Enzon Inc | Conjugados melhorados de interferao-polimero |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| JP2006213597A (ja) | 2000-07-19 | 2006-08-17 | Pepgen Corp | インターフェロン−タウを用いるｃ型肝炎ウイルスの処置のための組成物およびモニタリングの方法 |
| BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
| AU2006255122B2 (en) | 2005-06-03 | 2010-10-21 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| US7695710B2 (en) * | 2005-06-20 | 2010-04-13 | Pepgen Corporation | Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs |
| WO2009046080A1 (en) | 2007-10-01 | 2009-04-09 | Pharmaessentia Corp. | N-terminal modified interferon-alpha |
| EP2318029B1 (en) | 2008-07-23 | 2017-11-01 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
| CN104262480B (zh) * | 2014-09-28 | 2018-03-27 | 重庆理工大学 | 重组猪长效‑α干扰素的构建和修饰方法及其冻干注射剂的制备方法 |
-
2017
- 2017-06-16 CN CN202310995289.4A patent/CN117024562A/zh active Pending
- 2017-06-16 JP JP2018566519A patent/JP7093311B2/ja active Active
- 2017-06-16 CN CN201780051072.0A patent/CN109641034B/zh active Active
- 2017-06-16 CA CA3028683A patent/CA3028683A1/en active Pending
- 2017-06-16 AU AU2017280958A patent/AU2017280958A1/en not_active Abandoned
- 2017-06-16 EA EA201892671A patent/EA036509B1/ru unknown
- 2017-06-16 NZ NZ749962A patent/NZ749962A/en unknown
- 2017-06-16 KR KR1020187036853A patent/KR102409470B1/ko active Active
- 2017-06-16 ES ES17734584T patent/ES2793773T3/es active Active
- 2017-06-16 KR KR1020227019809A patent/KR102518451B1/ko active Active
- 2017-06-16 PT PT177345840T patent/PT3471755T/pt unknown
- 2017-06-16 DK DK17734584.0T patent/DK3471755T3/da active
- 2017-06-16 MX MX2018016295A patent/MX391970B/es unknown
- 2017-06-16 EP EP17734584.0A patent/EP3471755B1/en active Active
- 2017-06-16 US US16/311,540 patent/US10960080B2/en active Active
- 2017-06-16 BR BR112018076437A patent/BR112018076437A2/pt unknown
- 2017-06-16 PL PL17734584T patent/PL3471755T3/pl unknown
- 2017-06-16 WO PCT/US2017/037964 patent/WO2017222940A1/en not_active Ceased
-
2018
- 2018-12-11 ZA ZA2018/08352A patent/ZA201808352B/en unknown
- 2018-12-19 CL CL2018003697A patent/CL2018003697A1/es unknown
-
2021
- 2021-02-26 US US17/186,642 patent/US20210177980A1/en active Pending
- 2021-09-06 AU AU2021229132A patent/AU2021229132B2/en active Active
-
2022
- 2022-06-17 JP JP2022098147A patent/JP7441892B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519553A5 (enExample) | ||
| JP7441892B2 (ja) | ペグ化ブタインターフェロンおよびその使用方法 | |
| EA019965B1 (ru) | Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином | |
| WO2014139359A1 (zh) | 乙型肝炎疫苗 | |
| US20220023287A1 (en) | Treatment of hepatitis delta virus infection | |
| Liu et al. | Interferon as a mucosal adjuvant for an influenza vaccine in pigs | |
| JP2023517616A (ja) | 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤 | |
| US8263562B2 (en) | Peptides for preventing or treating liver damage | |
| US11304989B2 (en) | Peptides for use in the treatment of viral infections | |
| EP1797112B1 (en) | Inhibitors of hepatitits c virus | |
| US20150165009A1 (en) | Tlr5 ligands, therapeutic methods, and compositions related thereto | |
| JP2020518588A5 (enExample) | ||
| JP2014524450A5 (enExample) | ||
| JP2009515933A (ja) | インフルエンザにおけるインターフェロン | |
| JP2007537280A (ja) | 免疫調節性化合物を用いる呼吸器のウイルス感染の治療又は予防 | |
| FANG et al. | Prokaryotic Expression and Anti‑PRRSV Activity Study of Porcine IFN‑α8 | |
| EA008766B1 (ru) | Интерферон-бета при тяжелом остром респираторном синдроме (sars) | |
| Sattoju et al. | Major Viral Outbreaks in the 1st Decade of 21st Century-Literature Review | |
| US20230277650A1 (en) | Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv) | |
| JPH02304100A (ja) | ブタの肺炎または関連細菌病の予防または治療に使用するためのインターフェロン | |
| Mohammed et al. | Therapeutic challenges of COVID-19: strategies of empirical treatment | |
| CN116685598A (zh) | 干扰素taufc-融合蛋白和治疗方法冠状病毒感染 | |
| HK1087358A (en) | Interferon beta in severe acute respiratory syndrome (sars) |